Alveolar Macrophage Proteomics in HIV-associated Emphysema (HIVE)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by Ohio State University.
Recruitment status was Active, not recruiting
Information provided by (Responsible Party):
Philip Diaz, The Ohio State University
First received: January 15, 2009
Last updated: October 24, 2012
Last verified: October 2012
This study is being done to examine lung function changes in individuals with HIV infection and to understand why individuals with HIV have increased risk of lung damage from cigarette smoking.
||Observational Model: Case Control
Time Perspective: Prospective
||Alveolar Macrophage Proteomics in HIV-associated Emphysema
Biospecimen Retention: Samples With DNA
blood lung fluid (optional)
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||March 2013 (Final data collection date for primary outcome measure)
HIV smokers with emphysema
HIV smokers without emphysema
To delineate the natural history of HIV associated emphysema in the HAART era. To compare the alveolar macrophage proteomes from HIV-seropositive smokers with emphysema to the alveolar macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers.
To establish whether coinfection with HIV and Hepatitis C results in accelerated lung disease manifested by decrements in forced expiratory volume and carbon monoxide diffusing capacity.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Clinically stable HIV-seropositive (and HIV-seronegative) individuals
- Ages 18 years and older
- Female subjects on no oral contraception with a negative pregnancy test
- Subjects capable of giving written consent
- Known medical illness that would preclude bronchoscopy/BAL (e.g. unstable angina, new cardiac arrhythmia). This only pertains to subjects involved in the bronchoscopy phase of the study.
- Pregnant females
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00823927
|The Ohio State University
|Columbus, Ohio, United States, 43026 |
||Philip T Diaz, MD
||Ohio State University
No publications provided
||Philip Diaz, MD, The Ohio State University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 15, 2009
||October 24, 2012
||United States: Institutional Review Board
Keywords provided by Ohio State University:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 25, 2014
Acquired Immunodeficiency Syndrome
Immune System Diseases
Immunologic Deficiency Syndromes
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
RNA Virus Infections
Respiratory Tract Diseases
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases